Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19.

Abstract

We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle.

• Authors: Milad Zandi, Saber Soltani
• Journal: Molecular diversity (Mol Divers) Vol. 25 Issue 3 Pg. 1999-2000 (Aug 2021) ISSN: 1573-501X [Electronic] Netherlands
• PMID: 34241772 (Publication Type: Letter)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Antiviral Agents
• Hemagglutinins, Viral
• Viral Fusion Proteins
• hemagglutinin esterase

Topics

• Antiviral Agents (pharmacology, therapeutic use)
• COVID-19 (genetics, metabolism)
• Drug Design
• Genome, Viral (genetics)
• Hemagglutinins, Viral (genetics, metabolism)
• Molecular Targeted Therapy
• Viral Fusion Proteins (genetics, metabolism)
• COVID-19 Drug Treatment